CClinicalTrials.gg
CompletedNCT05240235Updated Jul 11, 2024

The Effect of Manual Lymph Drainage in the Treatment of Breast Edema

An interventional study of Education, compression and exercise therapy and Education, compression and exercise therapy manual lymph drainage in Breast Cancer and Rehabilitation, sponsored by Acibadem University. Completed at 1 site in Turkey. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-07-11.

Sponsored by Acibadem University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Study summary

Breast conserving surgery (BCS) is widely used in the treatment of breast cancer. Breast edema can be seen frequently after BCS and radiotherapy applications. Breast edema affects quality of life and may result in a cosmetically unsatisfactory outcome for the patient. Therefore, it is important to treat and prevent its development. In the light of this information, the present randomized controlled study aims to determine the effect of manual lymph drainage method in the treatment of breast edema in patients undergoing breast-conserving surgery and adjuvant radiotherapy.

02

Conditions studied

  • Breast Cancer and Rehabilitation
03

In context

Lead sponsor

Acibadem University is the lead sponsor of 210 studies on the registry; 50 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  1. Patients who underwent breast-conserving surgery and received adjuvant radiotherapy
  2. Patients with Sentinel Lymph Node Biopsy or axillary lymph node dissection
  3. Female patients between the ages of 18-75
  4. Patients who cannot read and write Turkish

Exclusion criteria

Exclusion Criteria:

  1. A previous cancer
  2. Decompensated heart failure
  3. Untreated congestive heart failure
  4. Active infection
  5. Uncontrolled hypertension
  6. Acute kidney failure
  7. Patients with acute deep vein thrombosis
  8. Metastasis and/or recurrence during treatment
  9. Patients who have undergone another surgery related to the breast and chest area
  10. Patients who develop lymphedema in the upper extremity during therapy will be excluded from the study.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Active comparator
    Education, compression and exercise therapy

    Patients will be given exercise therapy every day for the first two weeks. Afterwards, patients will be taken to the same therapy in the hospital for 1 day a week, and on other days they will do home exercise at home for 10 minutes.

    Other: Education, compression and exercise therapy

  • Active comparator
    Education, compression,exercise therapy and manual lymph drainage

    Patients will be given manual lymph drainage for one and a half hours every day for the first two weeks. Afterwards, patients will be taken to the same therapy in the hospital for 1 day a week, and on other days they will do self manual lymph drainage at home for 10 minutes.

    Other: Education, compression and exercise therapy manual lymph drainage

Interventions

  • OtherEducation, compression and exercise therapy

    Education; It includes information about the disease, information about risk factors, information that one should pay attention to, and skin care. For compression, sponge-shaped pads that create compression into the bra and prepared by the lymphedema physiotherapist will be used. The exercises will include breathing and upper extremity joint movement exercises determined by Casley-Smith, and the other days to be applied by the physiotherapist when the patient comes to the session will be applied by the patient once a day at home.

  • OtherEducation, compression and exercise therapy manual lymph drainage

    Education; It includes information about the disease, information about risk factors, information that one should pay attention to, and skin care. For compression, sponge-shaped pads that create compression into the bra and prepared by the lymphedema physiotherapist will be used. The exercises will include breathing and upper extremity joint movement exercises determined by Casley-Smith, and the other days to be applied by the physiotherapist when the patient comes to the session will be applied by the patient once a day at home. In addition, patients will be given manual lymph drainage for one and a half hours every day for the first two weeks. Afterwards, patients will be taken to the same therapy in the hospital for 1 day a week, and on other days they will do self manual lymph drainage at home for 10 minutes.

06

What researchers measure

Primary outcomes

  1. LENT-SOMA criteria in breast edema

    Breast Cancer Conservative treatment core objective measurement. It has a score between 13-52 points. As the score increases, it is seen that breast edema worsens. A decrease in the score indicates improvement in breast edema.

    Time frame: Change from baseline LENT-SOMA criteria at 12 weeks

  2. Breast edema questionnaire

    Getting 8.5 points from the questionnaire is the cut-off point. There is no breast edema below 8.5, there is breast edema above 8.5. It has a score between 0-80 points.

    Time frame: Change from baseline breast edema questionnaire at 12 weeks

  3. Clinical features of breast cancer and breast edema

    The presence of breast fibrosis or edema, teleangiectasia or dyspigmentation will be scored on a 4-point categorical scale. The scale will be in the range of 0-16 points, high scores will indicate worsening of breast edema, and low scores will indicate improvement.

    Time frame: Change from baseline clinical features of breast cancer and breast edema at 12 weeks

  4. Qualitiy of Life - European Organization for Research and Treatment of Cancer EORTC- BR23

    The EORTC-BR23 is a breast-specific module that comprises of 23 questions to assess body image, sexual functioning, sexual enjoyment, future perspective, systemic therapy side effects, breast symptoms, arm symptoms and upset by hair loss.All scores will linearly transforme to a 0 to 100 scale. A high or healthy level of functioning is represented by a high functional score. More severe symptoms or problems are represented by high symptom scores or items.

    Time frame: Change from baseline Quality of life (EORTC- BR23) test at 12 weeks

Secondary outcomes

  1. Breast pain intensity will be measured with the Visual Analog Scale

    The scale is 10 cm long and is applied by specifying a point on the vertical or horizontal line with two different ends (0 = no pain, 10 = the most severe pain) corresponding to the severity of pain felt by the patient.

    Time frame: Change from baseline Visual Analog Scale test at 12 weeks

  2. Quality of life test (EORTC QOL-C30)

    It includes 30 items that are grouped into five scales functional (physical, social, emotional functioning, cognitive and role), three scales of symptoms (fatigue, pain, nausea and vomiting), a global scale of health / quality of life and a number of related individual items with the symptoms of the disease and its treatment, as well as an item of economic impact. The answers to the items on the scales refer to "last week," except the patient's physical functioning scale whose time frame is the present. These answers they obey a Likert format, which ranges from 1 ("Not at all") and 4 ("A lot")

    Time frame: Change from baseline Quality of life test (EORTC QOL-C30) at 12 weeks

07

Study locations

1 site
  • Acibadem University
    Istanbul, +90, Turkey
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05240235
Lead sponsor
Acibadem University
Responsible party
Nuray Alaca (Assoc Prof. Nuray Alaca, Acibadem University) — Principal investigator
First posted
Feb 15, 2022
Start date
Nov 21, 2023
Primary completion
Jun 15, 2024
Completion
Jul 10, 2024
Last update
Jul 11, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion